7-methoxy-1-oxy-4H-benzo[e][1,2,4]triazin-3-one | 27446-13-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 7-methoxy-1-oxy-4H-benzo[e][1,2,4]triazin-3-one
• 英文别名: 7-Methoxy-1-oxy-4H-benzo[e][1,2,4]triazin-3-on；7-methoxy-1-oxido-2H-1,2,4-benzotriazin-1-ium-3-one
• CAS: 27446-13-5
• 化学式: C₈H₇N₃O₃
• 分子量: 193.162
• InChiKey: HFFUBBXDFNDKCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  79.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-methoxy-1-oxy-4H-benzo[e][1,2,4]triazin-3-one 在 三氯氧磷 作用下， 以76%的产率得到3-氯-7-甲氧基-1,2,4-苯并三嗪1-氧化物
  参考文献：
  名称：

  3-Amino-1,2,4-benzotriazine-1,4-dioxide 衍生物的合成、结构和缺氧细胞毒性

  摘要：

  合成了一系列新型 3-氨基-1,2,4-苯并三嗪-1,4-二氧化物衍生物并筛选了它们对早幼粒细胞白血病HL-60、雄激素非依赖性前列腺肿瘤PC3、肝细胞癌Bel-7402的体外细胞毒性、人食道肿瘤 ECA-109 和人乳腺肿瘤 MCF-7 细胞系在缺氧和常氧条件下。大多数化合物在缺氧和常氧条件下都显示出更高的细胞毒活性。其中，与替拉扎明相比，化合物 61 和 62 显示出更有效的细胞毒活性和低氧选择性。

  DOI：

  10.1002/ardp.200600201
• 作为产物：
  描述：

  4-甲氧基-2-硝基乙酰苯胺 在 盐酸 、 三氟乙酸 、 sodium nitrite 作用下， 以 乙醚 、 水 为溶剂， 反应 8.0h， 生成 7-methoxy-1-oxy-4H-benzo[e][1,2,4]triazin-3-one
  参考文献：
  名称：

  Discovery and Optimization of Benzotriazine Di-N-Oxides Targeting Replicating and Nonreplicating Mycobacterium tuberculosis

  摘要：

  Compounds bactericidal against both replicating and nonreplicating Mtb may shorten the length of TB treatment regimens by eliminating infections more rapidly. Screening of a panel of antimicrobial and anticancer drug classes that are bioreduced into cytotoxic species revealed that 1,2,4-benzotriazine di-N-oxides (BTOs) are potently bactericidal against replicating and nonreplicating Mtb. Medicinal chemistry optimization, guided by semiempirical molecular orbital calculations, identified a new lead compound (20q) from this series with an MIC of 0.31 mu g/mL against H37Rv and a cytotoxicity (CC50) against Vero cells of 25 mu g/mL. 20q also had equivalent potency against a panel of single-drug resistant strains of Mtb and remarkably selective activity for Mtb over a panel of other pathogenic bacterial strains. 20q was also negative in a L5178Y MOLY assay, indicating low potential for genetic toxicity. These data along with measurements of the physiochemical properties and pharmacokinetic profile demonstrate that BTOs have the potential to be developed into a new class of antitubercular drugs.

  DOI：

  10.1021/jm300123s

文献信息

• Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments
  申请人：Auckland Uniservices Limited

  公开号：EP1468688A2

  公开（公告）日：2004-10-20

  The present invention relates to a synergetistic composition comprising one or more benzoazine-mono-N-oxides, and one or more benzoazine 1,4 dioxides for use in cancer therapy. The invention also provides a range of novel 1,2,4 benzoazine-mono-N-oxides and related analogues. These can be used as potentiators of the cytotoxicity of existing anticancer drugs and therapies for cancer treatment.

  本发明涉及一种协同组合物，包括一种或多种苯并噁唑-单-N-氧化物，以及一种或多种苯并噁唑1,4-二氧化物，用于癌症治疗。 该发明还提供了一系列新颖的1,2,4苯并噁唑-单-N-氧化物及相关类似物。这些可以用作增强现有抗癌药物的细胞毒性和癌症治疗的治疗剂。
• Synthesis, Structure and Hypoxic Cytotoxicity of 3-Amino-1,2,4-benzotriazine-1,4-dioxide Derivatives
  作者：Faqin Jiang、Qinjie Weng、Rong Sheng、Qing Xia、Qiaojun He、Bo Yang、Yongzhou Hu

  DOI：10.1002/ardp.200600201

  日期：2007.5

  3‐amino‐1,2,4‐benzotriazine‐1,4‐dioxide derivatives were synthesized and screened for their in vitro cytotoxicity against promyelocytic leukemia HL‐60, androgen‐independent prostate tumor PC3, hepatocellular carcinoma Bel‐7402, human esophagus tumor ECA‐109, and human breast tumor MCF‐7 cell lines in hypoxia and in normoxia. Most compounds showed higher cytotoxic activity both in hypoxia and in normoxia

  合成了一系列新型 3-氨基-1,2,4-苯并三嗪-1,4-二氧化物衍生物并筛选了它们对早幼粒细胞白血病HL-60、雄激素非依赖性前列腺肿瘤PC3、肝细胞癌Bel-7402的体外细胞毒性、人食道肿瘤 ECA-109 和人乳腺肿瘤 MCF-7 细胞系在缺氧和常氧条件下。大多数化合物在缺氧和常氧条件下都显示出更高的细胞毒活性。其中，与替拉扎明相比，化合物 61 和 62 显示出更有效的细胞毒活性和低氧选择性。
• Stille Coupling Reactions in the Synthesis of Hypoxia-Selective 3-Alkyl-1,2,4-Benzotriazine 1,4-Dioxide Anticancer Agents
  作者：Karin Pchalek、Michael P. Hay

  DOI：10.1021/jo060986g

  日期：2006.8.1

  The introduction of a 3-alkyl substituent is a key step in the synthesis of 1,2,4-benzotriazine 1,4-dioxide hypoxia-selective anticancer agents, such as SN29751. The Stille reaction of 3-chloro-1,2,4-benzotriazine 1-oxides ( BTOs) 5 was inhibited by the presence of electron donating substituents on the benzo ring, thus limiting the range of compounds available for SAR studies. The use of 3-iodo-BTOs 8 did not provide a significant improvement in the yields of 3-ethyl-BTOs 6. Microwave-assisted Stille coupling of chlorides 5 gave dramatically improved yields, which were consistently superior to those from the corresponding iodides 8. The application of microwave-assisted synthesis extended the range of substituted BTOs available for SAR studies and provided an efficient, scalable synthesis of the investigational anticancer agent, SN29751 ( 1).
• Syntheses in the 1,2,4-Benzotriazine Series
  作者：JAMES JIU、GEORGE P. MUELLER

  DOI：10.1021/jo01088a021

  日期：1959.6
• Discovery and Optimization of Benzotriazine Di-<i>N</i>-Oxides Targeting Replicating and Nonreplicating Mycobacterium tuberculosis
  作者：Sidharth Chopra、Gary A. Koolpe、Arlyn A. Tambo-ong、Karen N. Matsuyama、Kenneth J. Ryan、Tran B. Tran、Rupa S. Doppalapudi、Edward S. Riccio、Lalitha V. Iyer、Carol E. Green、Baojie Wan、Scott G. Franzblau、Peter B. Madrid

  DOI：10.1021/jm300123s

  日期：2012.7.12

  Compounds bactericidal against both replicating and nonreplicating Mtb may shorten the length of TB treatment regimens by eliminating infections more rapidly. Screening of a panel of antimicrobial and anticancer drug classes that are bioreduced into cytotoxic species revealed that 1,2,4-benzotriazine di-N-oxides (BTOs) are potently bactericidal against replicating and nonreplicating Mtb. Medicinal chemistry optimization, guided by semiempirical molecular orbital calculations, identified a new lead compound (20q) from this series with an MIC of 0.31 mu g/mL against H37Rv and a cytotoxicity (CC50) against Vero cells of 25 mu g/mL. 20q also had equivalent potency against a panel of single-drug resistant strains of Mtb and remarkably selective activity for Mtb over a panel of other pathogenic bacterial strains. 20q was also negative in a L5178Y MOLY assay, indicating low potential for genetic toxicity. These data along with measurements of the physiochemical properties and pharmacokinetic profile demonstrate that BTOs have the potential to be developed into a new class of antitubercular drugs.